Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.

Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, Raiko I, Del Razo LM, Taeger D, Calderón-Aranda ES, Rihs HP, Acosta-Saavedra LC, Weber DG, Cabello-López A, Pesch B, Ochoa-Vázquez MD, Burek K, Torre-Bouscoulet L, Pérez-Padilla JR, García-Bazan EM, Brüning T, Johnen G, Aguilar-Madrid G.

Lung. 2019 Oct;197(5):641-649. doi: 10.1007/s00408-019-00244-1. Epub 2019 Jul 2.

PMID:
31267149
2.

Multi-walled carbon nanotubes induce stronger migration of inflammatory cells in vitro than asbestos or granular particles but a similar pattern of inflammatory mediators.

Westphal GA, Rosenkranz N, Brik A, Weber D, Föhring I, Monsé C, Kaiser N, Hellack B, Mattenklott M, Brüning T, Johnen G, Bünger J.

Toxicol In Vitro. 2019 Aug;58:215-223. doi: 10.1016/j.tiv.2019.03.036. Epub 2019 Mar 27.

3.

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.

Weber DG, Brik A, Casjens S, Burek K, Lehnert M, Pesch B, Taeger D, Brüning T, Johnen G; MoMar study group.

BMC Res Notes. 2019 Feb 11;12(1):77. doi: 10.1186/s13104-019-4113-7.

4.

Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Johnen G, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, Lehnert M, Casjens S, Hagemeyer O, Taeger D, Brüning T; MoMar Study Group.

Sci Rep. 2018 Sep 25;8(1):14321. doi: 10.1038/s41598-018-32315-3.

5.

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, Ochoa-Vázquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, García-Figueroa J, Alvarado-Cabrero I, Castillo-González P, Báez-Saldaña AR, Pérez-Padilla JR, Osnaya-Juárez J, Rivera-Rosales RM, García-Bazán EM, Bautista-Aragón YL, Lazcano-Hernandez E, Munguía-Canales DA, Argote-Greene LM, Taeger D, Weber DG, Casjens S, Raiko I, Brüning T, Johnen G.

Int J Med Sci. 2018 Jun 4;15(9):883-891. doi: 10.7150/ijms.23939. eCollection 2018.

6.

Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners.

Rosenberger A, Hung RJ, Christiani DC, Caporaso NE, Liu G, Bojesen SE, Le Marchand L, Haiman CA, Albanes D, Aldrich MC, Tardon A, Fernández-Tardón G, Rennert G, Field JK, Kiemeney B, Lazarus P, Haugen A, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Brunnsstöm H, Goodman GE, Doherty JA, Chen C, Teare MD, Wichmann HE, Manz J, Risch A, Muley TR, Johansson M, Brennan P, Landi MT, Amos CI, Pesch B, Johnen G, Brüning T, Bickeböller H, Gomolka M.

Int Arch Occup Environ Health. 2018 Nov;91(8):937-950. doi: 10.1007/s00420-018-1334-3. Epub 2018 Jul 3.

7.

Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.

Walter RFH, Rozynek P, Casjens S, Werner R, Mairinger FD, Speel EJM, Zur Hausen A, Meier S, Wohlschlaeger J, Theegarten D, Behrens T, Schmid KW, Brüning T, Johnen G.

PLoS One. 2018 May 31;13(5):e0195716. doi: 10.1371/journal.pone.0195716. eCollection 2018.

8.

Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine.

Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G.

Int J Mol Sci. 2018 Jan 11;19(1). pii: E226. doi: 10.3390/ijms19010226.

9.

Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.

Casjens S, Weber DG, Johnen G, Raiko I, Taeger D, Meinig C, Moebus S, Jöckel KH, Brüning T, Pesch B.

BMJ Open. 2017 Oct 11;7(10):e017104. doi: 10.1136/bmjopen-2017-017104.

10.

Calretinin as a blood-based biomarker for mesothelioma.

Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, Musk AW, Robinson BWS, Brüning T, Creaney J.

BMC Cancer. 2017 May 30;17(1):386. doi: 10.1186/s12885-017-3375-5.

11.

A recombinant polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma.

Raiko I, Rihs HP, Gleichenhagen J, Sander I, Kollmeier J, Lehnert M, Brüning T, Johnen G.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):526-532. doi: 10.1016/j.bbrc.2017.03.077. Epub 2017 Mar 19.

12.

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.

Weber DG, Gawrych K, Casjens S, Brik A, Lehnert M, Taeger D, Pesch B, Kollmeier J, Bauer TT, Johnen G, Brüning T.

Dis Markers. 2017;2017:9280170. doi: 10.1155/2017/9280170. Epub 2017 Feb 21.

13.

Incidence of malignant mesothelioma in Germany 2009-2013.

Lehnert M, Kraywinkel K, Heinze E, Wiethege T, Johnen G, Fiebig J, Brüning T, Taeger D.

Cancer Causes Control. 2017 Feb;28(2):97-105. doi: 10.1007/s10552-016-0838-y. Epub 2016 Dec 27.

PMID:
28025765
14.

Kinetics of chemotaxis, cytokine, and chemokine release of NR8383 macrophages after exposure to inflammatory and inert granular insoluble particles.

Schremmer I, Brik A, Weber DG, Rosenkranz N, Rostek A, Loza K, Brüning T, Johnen G, Epple M, Bünger J, Westphal GA.

Toxicol Lett. 2016 Nov 30;263:68-75. doi: 10.1016/j.toxlet.2016.08.014. Epub 2016 Aug 24.

PMID:
27565850
15.

Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.

Weber DG, Casjens S, Johnen G, Bryk O, Raiko I, Pesch B, Kollmeier J, Bauer TT, Brüning T.

PLoS One. 2014 Dec 3;9(12):e114483. doi: 10.1371/journal.pone.0114483. eCollection 2014.

16.

Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study.

Bonberg N, Pesch B, Behrens T, Johnen G, Taeger D, Gawrych K, Schwentner C, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Oberlinner C, Stenzl A, Brüning T.

BMC Cancer. 2014 Nov 20;14:854. doi: 10.1186/1471-2407-14-854.

17.

[Role of pretherapeutic biomarkers in lung cancer with special regards to bronchoscopic procedures].

Darwiche K, Özkan F, Ting S, Johnen G, Brüning T, Soltermann A, Huber LC, Christoph DC, Freitag L, Franzen D.

Pneumologie. 2014 Nov;68(11):719-26. doi: 10.1055/s-0034-1377299. Epub 2014 Jul 8. Review. German.

18.

Biomarker research with prospective study designs for the early detection of cancer.

Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T.

Biochim Biophys Acta. 2014 May;1844(5):874-83. doi: 10.1016/j.bbapap.2013.12.007. Epub 2013 Dec 17. Review.

PMID:
24361552
19.

Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer.

Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jöckel KH, Kollmeier J, Brüning T.

BMC Res Notes. 2013 Dec 6;6:518. doi: 10.1186/1756-0500-6-518.

20.

Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.

Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G, Nasterlack M, Lotan Y, Stenzl A, Brüning T; UroScreen Study Group.

Int Arch Occup Environ Health. 2014;87(7):715-24. doi: 10.1007/s00420-013-0916-3. Epub 2013 Oct 16.

PMID:
24129706
21.

Cross-contamination of a UROtsa stock with T24 cells--molecular comparison of different cell lines and stocks.

Johnen G, Rozynek P, von der Gathen Y, Bryk O, Zdrenka R, Johannes C, Weber DG, Igwilo-Okuefuna OB, Raiko I, Hippler J, Brüning T, Dopp E.

PLoS One. 2013 May 17;8(5):e64139. doi: 10.1371/journal.pone.0064139. Print 2013.

22.

Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study.

Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group.

BJU Int. 2013 Aug;112(4):E372-82. doi: 10.1111/j.1464-410X.2012.11666.x. Epub 2013 Jan 25.

23.

NOTCH1, HIF1A and other cancer-related proteins in lung tissue from uranium miners--variation by occupational exposure and subtype of lung cancer.

Pesch B, Casjens S, Stricker I, Westerwick D, Taeger D, Rabstein S, Wiethege T, Tannapfel A, Brüning T, Johnen G.

PLoS One. 2012;7(9):e45305. doi: 10.1371/journal.pone.0045305. Epub 2012 Sep 17.

24.

Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.

Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A; UroScreen Study Group.

Urol Oncol. 2013 Nov;31(8):1656-62. doi: 10.1016/j.urolonc.2012.04.015. Epub 2012 May 22.

PMID:
22621963
25.

Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen.

Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhäußer H, Eberle F, Nasterlack M, Leng G, Stenzl A, Brüning T; UroScreen Study Group.

PLoS One. 2012;7(4):e35363. doi: 10.1371/journal.pone.0035363. Epub 2012 Apr 16.

26.

Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A; UroScreen Study Group.

BJU Int. 2012 Sep;110(5):699-708. doi: 10.1111/j.1464-410X.2011.10883.x. Epub 2012 Feb 7.

27.

Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study.

Weber DG, Johnen G, Bryk O, Jöckel KH, Brüning T.

PLoS One. 2012;7(1):e30221. doi: 10.1371/journal.pone.0030221. Epub 2012 Jan 11.

28.

Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies.

Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, Olsson A, Ahrens W, Gross IM, Brüske I, Wichmann HE, Merletti F, Richiardi L, Simonato L, Fortes C, Siemiatycki J, Parent ME, Consonni D, Landi MT, Caporaso N, Zaridze D, Cassidy A, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Stücker I, Fabianova E, Dumitru RS, Bencko V, Foretova L, Janout V, Rudin CM, Brennan P, Boffetta P, Straif K, Brüning T.

Int J Cancer. 2012 Sep 1;131(5):1210-9. doi: 10.1002/ijc.27339. Epub 2011 Dec 14.

29.

[Bladder cancer screening with urine-based tumour markers - occupational medical experience].

Nasterlack M, Feil G, Leng G, Pesch B, Huber S, Sievert KD, Johnen G, Taeger D, Mayer T, Kluckert M, Brüning T, Stenzl A.

Aktuelle Urol. 2011 Mar;42(2):128-34. doi: 10.1055/s-0031-1271424. Epub 2011 Mar 24. German.

PMID:
21437837
30.

Association between lymph node silicosis and lung silicosis in 4,384 German uranium miners with lung cancer.

Taeger D, Brüning T, Pesch B, Müller KM, Wiethege T, Johnen G, Wesch H, Dahmann D, Hoffmann W.

Arch Environ Occup Health. 2011;66(1):34-42. doi: 10.1080/19338244.2010.506494.

PMID:
21337184
31.

The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines.

Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T; UroScreen Group.

BJU Int. 2011 Aug;108(4):546-52. doi: 10.1111/j.1464-410X.2010.09971.x. Epub 2011 Jan 11. Erratum in: BJU Int. 2011 Oct;108(7):1232.

32.

Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks.

Weber DG, Casjens S, Rozynek P, Lehnert M, Zilch-Schöneweis S, Bryk O, Taeger D, Gomolka M, Kreuzer M, Otten H, Pesch B, Johnen G, Brüning T.

Biomark Insights. 2010 Sep 22;5:95-102.

33.

Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.

Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.

Arch Toxicol. 2011 Mar;85(3):185-92. doi: 10.1007/s00204-010-0580-2. Epub 2010 Aug 25.

PMID:
20737138
34.

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.

Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, Scherpereel A, Brüning T, Johnen G.

BMC Cancer. 2010 May 28;10:242. doi: 10.1186/1471-2407-10-242.

35.

Clinical experience with survivin as a biomarker for urothelial bladder cancer.

Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A, Brüning T.

World J Urol. 2010 Jun;28(3):399-404. doi: 10.1007/s00345-010-0538-2. Epub 2010 Mar 23.

PMID:
20309562
36.

Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Brüning T, Gube M.

Biomark Insights. 2010 Jan 28;5:1-8.

37.

Cancer mortality in a surveillance cohort of German males formerly exposed to asbestos.

Pesch B, Taeger D, Johnen G, Gross IM, Weber DG, Gube M, Müller-Lux A, Heinze E, Wiethege T, Neumann V, Tannapfel A, Raithel HJ, Brüning T, Kraus T.

Int J Hyg Environ Health. 2010 Jan;213(1):44-51. doi: 10.1016/j.ijheh.2009.09.001. Epub 2009 Sep 26.

PMID:
19783208
38.

Major histopathological patterns of lung cancer related to arsenic exposure in German uranium miners.

Taeger D, Johnen G, Wiethege T, Tapio S, Möhner M, Wesch H, Tannapfel A, Müller KM, Brüning T, Pesch B.

Int Arch Occup Environ Health. 2009 Jul;82(7):867-75. doi: 10.1007/s00420-008-0386-1. Epub 2008 Nov 20.

PMID:
19020892
39.

A study on lung cancer mortality related to radon, quartz, and arsenic exposures in German uranium miners.

Taeger D, Krahn U, Wiethege T, Ickstadt K, Johnen G, Eisenmenger A, Wesch H, Pesch B, Bruning T.

J Toxicol Environ Health A. 2008;71(13-14):859-65. doi: 10.1080/15287390801987972.

PMID:
18569586
40.

Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.

Weber DG, Taeger D, Pesch B, Kraus T, Brüning T, Johnen G.

Cancer Biomark. 2007;3(6):287-92.

PMID:
18048966
41.

Occupational risks for adenocarcinoma of the nasal cavity and paranasal sinuses in the German wood industry.

Pesch B, Pierl CB, Gebel M, Gross I, Becker D, Johnen G, Rihs HP, Donhuijsen K, Lepentsiotis V, Meier M, Schulze J, Brüning T.

Occup Environ Med. 2008 Mar;65(3):191-6. Epub 2007 Sep 19.

PMID:
17881467
42.

Sclerosing pseudovascular rhabdomyosarcoma-immunohistochemical, ultrastructural, and genetic findings indicating a distinct subtype of rhabdomyosarcoma.

Kuhnen C, Herter P, Leuschner I, Mentzel T, Druecke D, Jaworska M, Johnen G.

Virchows Arch. 2006 Nov;449(5):572-8. Epub 2006 Oct 3.

PMID:
17016719
43.

Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency.

Brasch F, Schimanski S, Mühlfeld C, Barlage S, Langmann T, Aslanidis C, Boettcher A, Dada A, Schroten H, Mildenberger E, Prueter E, Ballmann M, Ochs M, Johnen G, Griese M, Schmitz G.

Am J Respir Crit Care Med. 2006 Sep 1;174(5):571-80. Epub 2006 May 25.

PMID:
16728712
44.

[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].

Krismann M, Thattamparambil P, Simon F, Johnen G.

Pathologe. 2006 Mar;27(2):99-105. German.

PMID:
16435096
45.

Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners.

Taeger D, Fritsch A, Wiethege T, Johnen G, Eisenmenger A, Wesch H, Ko Y, Stier S, Michael Muller K, Bruning T, Pesch B.

Cancer. 2006 Feb 15;106(4):881-9.

46.

Distribution of surfactant proteins in type II pneumocytes of newborn, 14-day old, and adult rats: an immunoelectron microscopic and stereological study.

Schmiedl A, Ochs M, Mühlfeld C, Johnen G, Brasch F.

Histochem Cell Biol. 2005 Dec;124(6):465-76. Epub 2005 Sep 27.

PMID:
16187065
47.

[Myoepithelioma of soft tissue -- case report with clinicopathologic, ultrastructural, and cytogenetic findings].

Kuhnen C, Herter P, Kasprzynski A, Vogt M, Jaworska M, Johnen G.

Pathologe. 2005 Sep;26(5):331-7. German.

PMID:
16032388
48.

Chromosomal alterations in early stages of malignant mesotheliomas.

Simon F, Johnen G, Krismann M, Müller KM.

Virchows Arch. 2005 Oct;447(4):762-7. Epub 2005 Oct 19.

PMID:
16012846
49.

[Lung cancer screening revisited -- are we merely combing a giraffe?].

Merget R, Johnen G, Pesch B, Brüning T.

Pneumologie. 2005 Mar;59(3):165-6. German. No abstract available.

PMID:
15756628
50.

Surfactant proteins in pulmonary alveolar proteinosis in adults.

Brasch F, Birzele J, Ochs M, Guttentag SH, Schoch OD, Boehler A, Beers MF, Müller KM, Hawgood S, Johnen G.

Eur Respir J. 2004 Sep;24(3):426-35.

Supplemental Content

Loading ...
Support Center